Salute e Benessere

SPRIM Global Investments and OneIM Announce $300mn Joint Venture to Accelerate…

Michael Shleifer, Co-Founder and Managing Partner of SPRIM Global Investments, said, "Our mission is to remove financial barriers that hinder biotech and medtech companies from focusing on research and development. Through this strategic partnership with OneIM, we are significantly expanding our ability to provide critical financing solutions that drive innovation in life sciences." Michael Shleifer, Co-Founder and Managing Partner of SPRIM Global Investments, said, "Our mission…
PR Newswire
10/03/2025

Zentiva takes legal action and challenges Urban Wastewater Treatment Directive…

In late 2024, the European Union adopted a significant update to the UWWTD. This revision aims to align the Directive with the Green Deal, addressing contemporary issues such as micropollutants and introducing the Extended Producer Responsibility (EPR) scheme. The Directive enforces the polluter pays principle, specifically requiring the pharmaceutical and cosmetic industries to finance the new quaternary treatment processes at urban wastewater treatment plants to remove these...
PR Newswire
10/03/2025

BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and…

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 and mRNA cancer immunotherapiesMultiple data readouts expected in 2025 and 2026 aimed at providing clinical proof of BioNTech's pipeline strategy and advancing the Company towards becoming a diversified multi-product oncology portfolio company by 2030Completed acquisition of...
Nasdaq GlobeNewswire
10/03/2025

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with…

Bagsværd, Denmark, 10 March 2025– Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The trial included 1,206 randomised people with obesity or overweight and type 2 diabetes and a mean baseline body weight of 102 kg.The trial...
Nasdaq GlobeNewswire
10/03/2025

Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support…

ORION CORPORATION PRESS RELEASE 10 March 2025 at 11.45 EET Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku Orion Corporation today announced that it is establishing a new research & development centre in Cambridge, UK during 2025 to accelerate its global growth strategy and the development of innovative medicines. The new centre will focus on the development of new biological and...
Nasdaq GlobeNewswire
10/03/2025

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug…

About Amlenetug About Amlenetug Amlenetug is a human monoclonal antibody (mAb) that recognizes and binds to all major forms of extracellular α-synuclein and thereby intended to prevent uptake and inhibit seeding of aggregation. Amlenetug has an active Fc region, which may increase immune-mediated clearance of α- synuclein /mAb complexes through microglia mediated uptake. Amlenetug is being developed by Lundbeck under a joint research and licensing agreement between Lundbeck and Genmab A/S...
PR Newswire
10/03/2025

Workout Clothes Market to Reach $344.4 billion, Globally, by 2035 at 5.6% CAGR…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A66713 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A66713 Prime determinants of growth Rise in health consciousness and fitness participation have driven the global workout clothes market, as more individuals engage in exercise routines, sports, and outdoor activities. The rising popularity of athleisure, where workout clothes are...
PR Newswire
10/03/2025

Isotopia Announces Official Commercial Launch of Isoprotrace® in Germany in…

Prostate cancer remains one of the most common cancers among men in Germany, with over 70,000 new cases diagnosed each year. Accurate imaging plays a crucial role in precise diagnosis and effective treatment planning. Prostate cancer remains one of the most common cancers among men inGermany, with over 70,000 new cases diagnosed each year. Accurate imaging plays a crucial role in precise diagnosis and effective treatment planning. "We are thrilled to be working with DSD Pharma to bring...
PR Newswire
10/03/2025

Tethis and Sheba Medical Center announce research collaboration to advance…

"Working with Sheba represents a significant step in expanding the applications of our liquid biopsy platform," states Dr. Holger Neecke, CEO of Tethis. "Our See.d instrument, combined with our nanocoated SmartBioSurface slides, enables standardized preparation of cytology specimens containing immune and tumor cells, suited for sequential multiplexing and interpretation with artificial intelligence, while collecting plasma for cell free DNA analysis." "Working with Sheba…
PR Newswire
10/03/2025

MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT…

"I am delighted to have Colby join and lead the company as we look to complete the REBALANCE study, a landmark investigational device exemption (IDE) clinical trial which is being conducted to support marketing authorization for our Ovarian Rebalancing procedure so that we can bring it to millions of women who experience PCOS-related infertility," commented Dr. Robert Auerbach, May Health Chairman. "Colby has deep experience bringing groundbreaking technologies to market, making…
PR Newswire
10/03/2025

Press Release: Dupixent late-breaking positive pivotal data in bullous…

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with...
Nasdaq GlobeNewswire
08/03/2025

Court Rules Voting Rights Restriction on Young Poong as Unlawful

SEOUL, South Korea, March 8, 2025 /PRNewswire/ -- The court has ruled that restricting Young Poong's voting rights at Korea Zinc's extraordinary shareholders' meeting on January 23 was unlawful, suspending the effectiveness of most resolutions passed, including the resolution to impose a cap on the number of directors. SEOUL, South Korea , March 8, 2025 /PRNewswire/ -- The court has ruled that restrictingYoung Poong'svoting rights at Korea Zinc's extraordinary shareholders' meeting...
PR Newswire
08/03/2025

Curia Announces Strategic Refinancing to Support Continued Growth

The transaction provides Curia with incremental capital and extends the maturities of its secured credit facilities, positioning the business for continued growth, allowing the company to capitalize on the attractive market opportunities in the drug development and manufacturing markets, and advancing its mission of partnering with biopharmaceutical customers to bring life-changing therapies to market."The refinancing demonstrates the confidence our lenders and investors have in Curia,”...
Nasdaq GlobeNewswire
07/03/2025

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March…

The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET / 1:00 PM CET. The call will include the Company's fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-225-9448International: +1-203-518-9708Conference ID: CLLS24Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1706599&tp_key=4524940f8f About...
Nasdaq GlobeNewswire
07/03/2025

Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest…

The Debenture matures two (2) years from the date of issuance (the "Maturity Date"), will bear interest at the rate of 10% per annum and is convertible into common shares of Innocan ("Common Shares") prior to the Maturity Date at a price of $0.21 per share (based on a foreign exchange rate on the day prior to the date of conversion). The Debenture is secured by a general security agreement and related security interest filed under the laws of the Province of Alberta as well…
PR Newswire
07/03/2025

Amino Acid Assay Kit Market to Reach USD 421.9 million by 2030, Growing at an…

Browse the report and understand how it can benefit your business strategy –https://www.credenceresearch.com/report/amino-acid-assay-kit-market Browse the report and understand how it can benefit your business strategy –https://www.credenceresearch.com/report/amino-acid-assay-kit-market Key Growth Determinants 1. Rising Prevalence of Metabolic Disorders Metabolic disorders, including amino acid metabolism disorders, phenylketonuria (PKU), and maple syrup urine disease...
PR Newswire
07/03/2025

Whoopi Goldberg Joins United Nations WPHF as Global Patron, Stands in Solidarity…

"I am proud to join WPHF as its Global Patron and stand alongside women who are fighting every day to create a world where peace and gender equality are the norm, not the exception," said Whoopi Goldberg. "The women supported by WPHF are the unsung heroes of our time—they fight for their lives, their families and their countries in the most challenging circumstances. I'm honored to be part of their journey, and I urge others to stand with us." "I am proud to join WPHF as…
PR Newswire
07/03/2025

BioLab Holdings, Inc. Announces Partnership with Real Collagen GmbH

Through this partnership, BioLab will develop new, novel products, initially in the wound healing space, with the goal to better address patient needs and augment and expand its portfolio of wound care offerings. Through this partnership, BioLab will develop new, novel products, initially in the wound healing space, with the goal to better address patient needs and augment and expand its portfolio of wound care offerings. Real Collagen GmbH possesses over 15 years of experience developing...
PR Newswire
07/03/2025

Virbac : Declaration of the number of shares and voting rights 02/25

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsFebruary, 28 20258 390 660Gross total of voting...
Nasdaq GlobeNewswire
07/03/2025

Pharmacy Automation Market worth US$10.00 billion by 2030 with 7.1% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71522890 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71522890 Browse in-depth TOC on "Pharmacy Automation Market" 200 - Tables 50 - Figures 300 - Pages By Based on product type,the pharmacy automation market has been segmented into automated medication dispensing and storage systems, automated packaging and labeling systems, automated tabletop counters,...
PR Newswire
07/03/2025

Breast Lesion Localization Market is expected to generate a revenue of USD…

Breast lesion localization plays a crucial role in guiding precise surgical interventions and improving patient outcomes in breast cancer treatment. With the rising prevalence of breast cancer and advancements in minimally invasive procedures, the demand for innovative localization techniques is on the rise. The report provides a detailed analysis of market dynamics, covering wire-guided localization (WGL), radiofrequency identification (RFID), electromagnetic, and magnetic-tracking…
PR Newswire
07/03/2025

Novartis shareholders approve all resolutions proposed by the Board of Directors…

Shareholders approved 28 thconsecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the Board of Directors as well as Elizabeth McNally as new member of the Board of Directors. Joerg Reinhardt, Charles L. Sawyers and William T. Winters did not stand for re-electionShareholders approved all other proposals by the Board of Directors, including the reduction of share...
Nasdaq GlobeNewswire
07/03/2025

Ulike Attends 2025 AAD Annual Meeting to Highlight IPL Technology Advancements

Ulike focuses on democratizing professional skincare with its advanced IPL technology. Founded in 2013, the company invests at least 30% of its annual profits in R&D and collaborates with experts to refine its products. By enabling clinic-grade, holistic treatments at home, Ulike promotes healthier skin and empowers confidence worldwide. It was honored the world's #1 at-home hair removal brand by Frost & Sullivan in 2023. Ulike focuses on democratizing professional skincare with its…
PR Newswire
07/03/2025

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Barclays 27th Annual Global Healthcare Conference, which will be held in Miami, Florida on March 11-13, 2025. Robert Wessman, founder, chairman and CEO and members of the management team will host one-on-one meetings. Alvotech will also be participating in a fireside chat on Wednesday, March 12, 2025, at…
Nasdaq GlobeNewswire
07/03/2025
Altri  Comunicati